Introduction
The Ras/Raf/MEK/ERK signaling pathway regulates cellular proliferation, differentiation, and survival (1) . Aberrant activation of this pathway, often caused by activating mutations in the composite enzymes, occurs in many tumors (2, 3) . In human cancer, mutations in RAF (mainly B-RAF) occur in approximately 60% of melanomas (3) and with lower frequency in papillary thyroid cancers (4), colorectal carcinomas (3, 5, 6) , and lung cancers (3) . This spectrum of malignancies is similar to that observed with RAS mutations, found in about 15%-30% of human cancers overall (3, 7, 8) , which indicates that dysregulation of the Ras/Raf/MEK/ERK pathway may be central to the genesis of these malignancies (2, 3) . It was recently shown that B-RAF mutant cells are considerably more sensitive to MEK inhibition than are either RAS mutant or B-RAF/RAS WT cells (9) . In the B-RAF mutant cells, MEK inhibition elicited potent cell cycle arrest and also apoptosis in some cases, but the mechanisms for cell killing were not examined.
Tumor cell apoptosis can occur via extrinsic (death receptor) or intrinsic (mitochondrial) cell death pathways (10) . Intrinsic apoptosis is regulated by the Bcl-2 family proteins, consisting of 3 subgroups: the prosurvival members, such as Bcl-2 or Mcl-1, the proapoptotic Bax/Bak subgroup, and the proapoptotic Bcl-2 homology 3-only (BH3-only) proteins. Apoptotic stimuli trigger activation of specific BH3-only proteins, which then engage the prosurvival Bcl-2 family members and liberate the downstream effectors, Bax and Bak, to elicit mitochondrial outer membrane permeabilization, unleashing the caspase cascade and culminating in cell demolition. Based on discoveries with other kinase inhibitors (11) (12) (13) (14) , we hypothesized that MEK inhibitors would kill
B-RAF mutant tumor cells by upregulating BH3-only proteins.
Here we present data demonstrating that MEK inhibitors kill B-RAF mutant tumor cells by upregulating the expression of the proapoptotic BH3-only protein Bim and present evidence that MEK inhibitors synergize with the BH3 mimetic ABT-737 to cause tumor cell apoptosis. Finally, we provide what we believe to be the first evidence that the combination of MEK inhibition and ABT-737 induces potent antitumor effects in vivo. (9) that the MEK inhibitor UO126 potently inhibited proliferation of the B-RAF mutant (V600E) tumor cell lines Colo205 and SkMel-28, but had little impact on the WT B-RAF PC3 tumor cell line (Figure 1A ). In addition, we found that following G 1 cell cycle arrest, a sizeable proportion of Colo205 and SkMel-28 cells underwent apoptosis, as indicated by sub-G 1 DNA content ( Figure 1 , A and B) as well as cleavage of PARP and caspase-3 ( Figure 1C ). The extent of tumor cell killing depended on the dose of the MEK inhibitor, correlated with reduced phosphorylation of ERK1/2 ( Figure 1C) , and was inhibited by the broad-spectrum caspase inhibitor QVD-OPH and by Bcl-2 overexpression ( Figure 1D ). These findings were reproduced with an independent MEK inhibitor, PD98059, although it was less potent than UO126 ( Figure 1C and data not shown). These results show that MEK inhibition caused cell cycle arrest and Bcl-2-regulated apoptosis (also called mitochondrial or intrinsic apoptosis) in B-RAF mutant tumor cells.
Results

MEK inhibition caused growth arrest and apoptosis in B-RAF mutant tumor cells. Initial studies confirmed the previous observation
MEK inhibition caused the induction of Bim in B-RAF mutant tumor cells. Because MEK inhibition-induced apoptosis of Colo205 cells
was blocked by Bcl-2 overexpression, we examined the expression of other Bcl-2 family members. Treatment with UO126 caused a rapid and sustained induction of Bim in Colo205 cells, but not in PC3 cells (Figure 2A ). Of the known isoforms of Bim that are generated by alternative splicing (15) , Bim EL was the most prominently expressed, but Bim L was also detected (Figure 2A ). The extent of Bim induction in Colo205 cells was dose dependent and correlated with the extent of ERK1/2 dephosphorylation ( Figure 2B ). No significant changes were observed in other BH3-only proteins (e.g., Bad, Bid, or Puma), proapoptotic Bax and Bak, or the prosurvival proteins Bcl-2, Bcl-w, Bcl-x L , and Mcl-1 ( Figure 2, A and B) ; prosurvival protein A1 was below the level of detection (data not shown). These results show that MEK inhibition caused specific induction of Bim in B-RAF mutant tumor cells.
MEK inhibition caused dephosphorylation of Bim in B-RAF mutant Colo205 cells. Activation of Bim often involves its dephosphoryla-
tion, resulting in a reduction in apparent molecular weight on SDS-PAGE analysis (16, 17) . Such a change in Bim EL was apparent after treatment of Colo205 cells with UO126 ( Figure 2, A and B) , and a change in Bim phosphorylation was supported by phosphatase treatment of cell lysates ( Figure 2C ). In contrast, similar analysis of PC3 cells revealed very little difference in the migration of Bim EL after MEK inhibition. Using phosphorylated Bad-specific antibodies, it was apparent that neither residue 112 nor residue 136 of Bad were substantially dephosphorylated in Colo205 cells after MEK inhibition ( Figure 2D ). These data indicate that Bim was constitutively phosphorylated in B-RAF mutant tumor cells and that MEK inhibition caused its specific dephosphorylation. Figure 1A ; supplemental material available online with this article; doi:10.1172/ JCI35437DS1). These Bim knockdown (KD) cells were protected from UO126-induced killing ( Figure 3B and Supplemental Figure  1A ), although not as potently as those overexpressing Bcl-2, most likely because of incomplete KD of Bim ( Figure 3A) . Importantly, the Bim KD and Bcl-2-overexpressing cells underwent dephosphorylation of ERK1/2 and cell cycle arrest in response to UO126 treatment, demonstrating that they still responded to MEK inhibition ( Figure 3A and data not shown). Bim KD and Bcl-2 overexpression had similar effects on the response to MEK inhibition in SkMel-28 melanoma cells, an independent B-RAF mutant tumor cell line (Supplemental Figure 1B) . Treatment with UO126 for 24 h caused an approximately 10-fold reduction in colony formation of parental Colo205 cells, which was blocked by both Bim KD and Bcl-2 overexpression ( Figure 3C ). However, after 48 h of UO126 treatment, only Bcl-2 overexpression provided protection against loss of clonogenicity, again most likely because of incomplete KD of Bim with longerterm MEK inhibition ( Figure 3A) . Collectively, these results demonstrate that Bim is essential for MEK inhibition-induced apoptosis and loss of clonogenicity of B-RAF mutant tumor cells.
MEK inhibition caused induction and dephosphorylation of Bim in a range of B-RAF mutant tumor cell lines. Next, we extended our analysis to 3 additional B-RAF mutant tumor cell lines: SkMel-28, MM200-1, and Mel-RMU. In all of these melanoma cell lines, profound dephosphorylation of ERK1/2 and robust induction of Bim were observed after MEK inhibition ( Figure 4A) . Similar to what we observed in Colo205 cells, analysis of the mobility of Bim on SDS-PAGE and treatment of lysates with λ phosphatase indicated that MEK inhibition caused dephosphorylation of Bim in SkMel-28 cells ( Figure 4B ). These data cement the notion that MEK inhibition causes Bim upregulation in B-RAF mutant tumor cells.
Induction of apoptosis requires efficient antagonism of all prosurvival Bcl-2 family members present in a given cell by BH3-only proteins (18) . Bim, unlike more selective BH3-only proteins (such as Bad), can bind with high affinity to all prosurvival Bcl-2 family members (19, 20) . Therefore, survival of MEK inhibitor-treated B-RAF mutant tumor cells, despite robust Bim induction, may be a consequence of high levels of prosurvival Bcl-2-like proteins and/ or very low levels of other BH3-only proteins. We therefore performed a comprehensive BH3-only protein and prosurvival Bcl-2-like protein analysis in these cells. This revealed that the SkMel-28, MM200-1, and Mel-RMU cell lines all contained lower basal levels of Bim and higher levels of phosphorylated ERK1/2, and the SkMel-28 and MM200-1 lines demonstrated higher levels of Bcl-2, than did the more sensitive Colo205 cells ( Figure 4C ). In contrast, they contained comparable levels of other Bcl-2 family members, including Bmf, Puma, Bad, Bax, Bak, and Mcl-1 ( Figure 4C ). Thus, the relative levels of Bim and Bcl-2 may contribute to the observed differences in sensitivity of the different B-RAF mutant cells to MEK inhibition-induced apoptosis.
The BH3 mimetic ABT-737 synergized with MEK inhibition in the killing of B-RAF mutant tumor cells. Since low levels of BH3-only proteins and/
or high levels of Bcl-2-like prosurvival proteins may limit the cyto- toxic activity of MEK inhibition ( Figure 3 and Figure 4C ), we sought to determine whether a BH3 mimetic, such as ABT-737 (21), could enhance killing of B-RAF mutant tumor cells. The MEK inhibitor sensitivity of a tumor cell line with a sensitive profile (i.e., Colo205; low Bcl-2 and high Bim) was further enhanced by the addition of ABT-737 in a dose-dependent manner, resulting in far greater killing than achieved with either drug alone ( Figure 5, A and B) . Apoptosis induced by this drug combination was blocked by QVD-OPH, which indicates that it was caspase dependent (data not shown). Because Bim KD and Bcl-2 overexpression rendered Colo205 cells resistant to MEK inhibition, we examined whether these cells could be resensitized by the addition of ABT-737. Treatment with ABT-737 or UO126 alone produced modest effects, but in combination, these drugs achieved killing of large fractions of Bim KD and even Bcl-2-overexpressing Colo205 cells ( Figure 5C ). Perhaps most striking was the ability of 1 μM ABT-737 to resensitize Bcl-2-overexpressing Colo205 cells, which were completely refractory to MEK inhibition alone ( Figure 5C ) and also resistant to etoposide-induced apoptosis (Supplemental Figure 2) . In support of our hypothesis that SkMel-28 and MM200-1 tumor cells are relatively resistant to MEK inhibition because they express comparatively low levels of Bim and high levels of Bcl-2, treatment with the combination of UO126 and ABT-737 resulted in substantially more apoptosis compared with treatment with either drug alone ( Figure 5D and Supplemental Figure 3 MEK inhibition and ABT-737 synergized to enhance survival of mice bearing B-RAF mutant tumors. Next we examined whether ABT-737 cooperates with MEK inhibition in the treatment of B-RAF mutant tumors in vivo. We used PD0325901, which has a much higher affinity for MEK and enhanced efficacy in vivo than does UO126 (22) . As anticipated, in vitro treatment of SkMel-28 or Colo205 tumor cells with 50 nM PD0325901 resulted in potent inhibition of ERK1/2, robust induction of Bim (Supplemental Figure 4) , and extensive apoptosis (data not shown). In mice bearing SkMel-28 tumors, after 48 h of in vivo treatment with either 3 mg/kg PD0325901 or with the combination of 3 mg/kg PD0325901 and 75 mg/kg ABT-737, robust induction of Bim was seen in the tumor cells ( Figure 6A ). Tumorbearing mice were treated for 10 d with the respective regimen, and no significant clinical toxicity was observed as evidenced by stable weight, normal behavior and hematologic analysis, although platelet levels fell initially, as expected, in the ABT-737 groups (Supplemental (PR), defined by tumor shrinkage of at least 50%, but less than 100% - in 2 of 10 mice for 2 d, and prevented tumor progression for about 1 wk after treatment had finished, whereas ABT-737 had no effect on its own ( Figure 6 , B and C). Remarkably, the combination of PD0325901 and ABT-737 resulted in profound inhibition of tumor growth, with tumor regression (complete response, i.e., 100% reduction, in 1 recipient mouse and PR in all 12 remaining mice) for a median of 7 d and a delay in tumor progression that persisted more than 9 wk after treatment stopped (median survival, 83 d for the combination versus 45 d for PD0325901 alone, P < 0.0007; increase in lifespan [ILS], 184% versus PD0325901 alone; Figure 6 , B and C; and ref. 24 ). ABT-737 and PD0325901 also cooperated in the treatment of nude mice bearing Colo205 tumors (median survival, 30 d for the combination versus 20 d for PD0325901 alone; ILS, 150% versus PD0325901 alone; P <0.005; Supplemental Figure 6 ). Furthermore, upon reaching the maximal tumor volume (predetermined according to animal ethics guidelines; see Methods), in retreatment studies with the same 10-d regimen PD0325901 alone - and, more strikingly, the combination of PD0325901 and ABT-737 - again elicited substantial tumor regression. Treatment with 3 mg/kg PD0325901 in SkMel-28 tumor-burdened mice resulted in PR in 0 of 2 mice compared with PR in 3 of 3 mice retreated with PD0325901 plus ABT-737; Colo205 tumor-burdened mice retreated with PD0325901 underwent PR in 1 of 3 mice, compared with PR in 2 of 2 mice retreated with PD0325901 plus ABT-737. This finding indicates that tumors remained susceptible to target inhibition at the time of relapse (Supplemental Figure 7) . Our results show that MEK inhibition and ABT-737 can synergize to produce impressive in vivo antitumor efficacy in mice bearing B-RAF mutant tumors.
Discussion
Our results show that 3 well-characterized MEK inhibitors, UO126, PD98059, and PD0325901, triggered apoptosis in B-RAF mutant, but not B-RAF WT, tumor cells. Although MEK inhibition-induced G 1 cell cycle arrest was similar in all 4 B-RAF mutant tumor cell lines examined, the extent of apoptosis was much more varied, in agreement with previously published work (9) . The extent of MEK inhibition correlated with the extent of loss of ERK1/2 phosphorylation and induction of 1 Bcl-2 family member, the proapoptotic BH3-only protein Bim.
The inactivation of ERK1/2 and induction of Bim were accompanied by a decrease in the apparent molecular weight of Bim, which was indicative of dephosphorylation, confirmed by λ phosphatase analysis. Because ERK1/2 can phosphorylate Bim, thereby priming it for ubiquitination and proteasomal degradation (25) (26) (27) , shutdown of this signaling pathway is likely to account for a major part of the accumulation of Bim. In agreement with this notion, the levels of ERK1/2 phosphorylation correlated inversely with the amount of Bim in our panel of 4 B-RAF mutant tumors ( Figure 4C ) and also in a selection of other cell lines (r 2 = 0.4495; Supplemental Figure 8 ). Furthermore, it was recently demonstrated that ERK1/2-mediated phosphorylation of Bim EL can also promote its rapid dissociation from prosurvival Bcl-2 family members (28) . We expect that MEK inhibitorinduced shutdown of this ERK1/2-mediated process promotes apoptosis in B-RAF mutant cells by facilitating the binding of Bim EL to prosurvival Bcl-2 family members.
Experiments using RNAi demonstrated that Bim was essential for MEK inhibition-induced killing and loss of clonogenic poten- tial of B-RAF mutant tumor cells. The level of protection afforded by Bim KD was comparable to that afforded by Bcl-2 overexpression at early time points, but it was considerably less efficient after more protracted MEK inhibition. This is likely the result of incomplete Bim KD, but it is also possible that activation of other BH3-only proteins or inactivation of prosurvival Bcl-2 family members contributed to MEK-induced tumor cell killing, although we saw no evidence in support of this possibility.
Apoptosis induction is thought to require antagonism of all prosurvival Bcl-2 family members expressed in a particular cell by BH3-only proteins (18) . We found that the B-RAF mutant tumor cells that were most resistant to MEK inhibitor-induced apoptosis expressed the lowest levels of Bim and the highest levels of Bcl-2. Therefore, inefficient tumor cell killing is probably a consequence of incomplete neutralization of Bcl-2.
We and others have previously shown that BH3 mimetics can potently collaborate with the EGF receptor tyrosine kinase inhibitor gefitinib (12) (13) (14) , and the BCR-ABL tyrosine kinase inhibitor imatinib (11) , in the treatment of tumor cells transformed by these oncogenic kinases. Shutdown of the MEK-ERK1/2 pathway was found to be critical for imatinib-induced (11) as well as gefitinib-induced (12-14) tumor cell killing. Accordingly, in the present study we found that ABT-737 synergized with MEK inhibition in the killing of B-RAF mutant tumor cells, even those that spontaneously or through experimental modification expressed abnormally high levels of Bcl-2 or low levels of Bim.
Previous work (9) showed that MEK inhibitors could cause growth arrest, although not substantial regression, of xenografted B-RAF mutant tumors in nude mice. Here, we found that the MEK inhibitor PD0325901 synergized with ABT-737 in vivo to cause prolonged regression of B-RAF mutant tumors in nude mice. The tumor growth delay achieved with combination treatment was highly significant compared with the effects observed with PD0325901 alone. Notably, these results were achieved with low doses of PD0325901, which produced minor growth-inhibitory effects when applied alone. In addition, tumors remained susceptible to retreatment with PD0325901 and, even more impressively, to retreatment with the combination of PD0325901 and ABT-737 at the time of tumor relapse, which indicates that extended treatment regimens may be even more efficacious.
Others have proposed that dephosphorylation of Bcl-2 is critical for the synergistic interaction between MEK inhibition and ABT-737 in the killing of acute myeloid leukemia cells (29) . This appears unlikely in Colo205 cells, since they express only very low levels of Bcl-2 ( Figure 4C ). Instead, we believe that ABT-737 liberates Bim (induced by MEK inhibition) and possibly other BH3-only proteins from Bcl-2 and Bcl-x L , thereby allowing efficient neutralization of all prosurvival Bcl-2 family members, including Mcl-1 and potentially A1, in the tumor cells.
Collectively, studies with tumor cells addicted to 3 different oncogenic kinases - BCR-ABL (11), mutated EGF-R (12-14) , and now mutated B-RAF - demonstrate that their killing by specific kinase inhibitors requires upregulation and dephosphorylation of Bim. A critical common component of the action of these drugs - imatinib, gefitinib, erlotinib, and MEK inhibitors - is the inhibition of ERK1/2, which is known to regulate the proapoptotic activity and level of Bim (17) . However, it is not clear why inhibition of MEK, and consequently ERK1/2, is not as potent in killing cells bearing RAS mutations. It may be that oncogenic RAS exerts prosurvival functions in addition to ERK1/2-mediated suppression of Bim that need to be antagonized in order to achieve efficient tumor cell killing. It is well known that Ras is able to activate a number of cellular targets, such as PI3K, Ras GDS, and Tiam-1 (reviewed in ref. 30) , some of which have established roles in driving tumorigenesis and preventing apoptosis. Perhaps the most obvious candidate is PI3K, which is known to activate the prosurvival AKT pathway (31), providing a straightforward explanation for the additional prosurvival capacity of Ras.
In conclusion, our results demonstrate that Bim is essential for MEK inhibition-induced killing of B-RAF mutant tumors and that addition of ABT-737 can overcome resistance of tumor cells to MEK inhibitors associated with low levels of Bim or high levels of Bcl-2. These in vivo data suggest that the combination of a MEK inhibitor and a BH3 mimetic could be a powerful new approach in the clinic for treating patients with tumors harboring B-RAF mutations, such as melanomas, which are commonly profoundly resistant to anticancer therapy (32) .
Methods
Cell lines, expression constructs, and cell transfection. Colo205 and HT-29 are cell lines derived from a colorectal tumor; PC3 is a prostate cancer cell line; MCF-7 is a breast cancer line; Ramos, Raji, and SU-DH-L4 are lymphoma cell lines; H1650 is a non-small cell lung cancer cell line; SkMel-28, MM200-1, A375, G361, UACC62, SkMel-31, and Mel-RMU are all melanoma Expression constructs for human FLAG-tagged Bcl-2 (33), the anti-Bim shRNA (34) , and a control scrambled shRNA construct (12) were described previously. The independent shRNA to human Bim and nonsilencing control shRNAs were gifts of the Victorian Centre for Functional Genomics.
Transfection with Fugene (Roche) was performed according to the manufacturer's instructions. Transfected cells were selected with 1 μg/ml puromycin and single-cell cloned by limiting dilution. FLAG-tagged proteins were detected by cytoplasmic immunofluorescence staining with anti-FLAG antibody (M2; Sigma-Aldrich) and flow cytometric analysis in a FACScan (BD).
Western blotting. Protein samples were separated by SDS-PAGE and then blotted onto PVDF membranes (Hybond P; Amersham Biosciences). The membranes were blocked with 5% nonfat dry milk in PBS with 0. Immunoprecipitation. For immunoprecipitation, cell lysates were first precleared by incubation for 2 h with protein G-sepharose (Amersham Biosciences) and then incubated for 2 h with anti-Bim (3C5) mAb-coupled sepharose beads. Beads were then washed before elution with 0.1 M glycine HCl (pH 2.7) followed by neutralization and boiling in loading buffer.
Cell death assays. Cell death was assessed by flow cytometric analysis following release of the cells from the culture dish through trypsinization, either by staining with propidium iodide plus FITC-conjugated annexin V or by measuring the percentage of cells that underwent DNA fragmentation (sub-G1 DNA), as detailed previously (35) . To compare between transfectants, we expressed apoptosis as percent of control, calculated as (1 - [100 - sample])/(100 - control). The latter technique was also used to assess changes in cell cycle distribution. For clonogenic survival assays, cells were seeded at 2.0 × 10 5 cells/ml and treated for 24 or 48 h with 20 μM UO126 (CST) in the presence or absence of ABT-737 (1 μM unless otherwise indicated). Cells were then trypsinized and washed to remove drugs before adding fresh medium and seeded at different cell densities (1-2,400 cells/well with at least 8 wells per cell density and treatment) in 96-well plates (Nunc). Clonogenicity was examined by counting the number of wells with colonies after 10-12 d of culture and performing linear regression analysis as previously reported (36) .
Animal studies. Athymic CBA nu/nu mice (6-8 wk old; WEHI animal breeding facility) were used for animal studies with approval from the Melbourne Health Animal Ethics Committee and the WEHI Animal Ethics Committee. Tumors were generated in mice by subcutaneous injection of 5 × 10 6 Colo205 or SkMel-28 tumor cells together with 10% (final v/v) Matrigel (BD Biosciences - Pharmingen). Tumor growth was monitored by measuring 2 perpendicular axes using calipers. After tumors had grown to the approved size (0.1 cm 3 for SkMel-28 or 0.2 cm 3 for Colo205, calculated as π/6 × [larger diameter × smaller diameter 2 ]), mice were randomized into 4 treatment groups: 3 mg/kg PD0325901 by oral gavage, 75 mg/kg ABT-737 intraperitoneally, both drugs, or vehicle only as a control. For tumor-bearing mice that were to be harvested 48 h after treatment, the tumors were allowed to grow to 0.3 cm 3 prior to treatment.
PD0325901 was formulated in 0.5% hydroxypropyl methylcellulose plus 0.2% Tween 80 and administered by oral gavage. ABT-737 was formulated as described previously (21) and injected intraperitoneally. Drugs were administered daily for 10 d, and tumor size was measured every 2-3 d. Mice were sacrificed when the tumors reached the target volume (0.5 cm 3 for SkMel-28 or 0.7 cm 3 for Colo205). Mice were weighed daily during therapy (days 1-10) and also if appearing unwell and at cull. No mice developed a significant change in weight (loss of more than 10% total body weight). Mice were bled for hematologic analysis at 16 h, 48 h, and 11 d as well as at cull. For a subset of mice, when tumors reached the predetermined end point (SkMel-28, 0.5 cm 3 ; Colo205, 0.7 cm 3 ), mice were retreated for a further 10 d with the same treatment regimen and/or were euthanized when tumors reached 0.8 cm 3 .
For biochemical analyses, tumors were dissected, prepared as a singlecell suspension, and snap frozen for lysis and subsequent assessment by Western blotting or immunoprecipitation. Effects on tumor growth delay were assessed by determining percent ILS, calculated as the ratio of median times for tumors to reach predetermined size x in treated/ control groups (26) .
Statistics. Prism software (version 5.0; GraphPad Software Inc.) was used for generating Kaplan-Meier statistical analysis (using a log-rank test) of survival of mice related to tumor size end point. P values of less than 0.05 were considered significant.
